Bayer's €2 Billion Hybrid Bond and the Missouri Ruling That Could Redefine the Investment Case

Bayer raised €2 billion in hybrid bonds as investors await a final Missouri court ruling on its glyphosate settlement, with Q2 revenue up 2.2%.

Bayer has been quietly rebuilding its financial architecture while the market waits on a single courtroom decision in Missouri. The two tracks — one on the balance sheet, one in the courts — now define how investors are pricing the Leverkusen conglomerate.

A €2 Billion Hybrid Issue Extends the Runway

On Wednesday, Bayer placed hybrid bonds totaling €2 billion, split into two tranches carrying coupons of 5.75% and 6.25%. Both tranches run for 30 years. The subordinated structure bolsters the group's financial profile without diluting existing shareholders' voting rights, and it lifts Bayer's total outstanding hybrid bond volume to €6.55 billion.

The proceeds give management added flexibility in servicing maturing debt — a step-by-step approach to balance sheet stabilization rather than a single dramatic fix. It also buys time, which matters given what is pending elsewhere.

Missouri Holds the Gavel on Glyphosate

The central variable for Bayer's medium-term equity story remains a binding resolution of the glyphosate litigation in the United States. Roughly two weeks ago, the Missouri Circuit Court held the hearing on final approval of the multibillion-dollar Roundup settlement, following an earlier preliminary green light from a judge at the Circuit Court in St. Louis. A final ruling is still outstanding and is expected at a later date.

That pending decision is where the risk premium that has kept the DAX group trading at a discount for years gets settled. Until a legally binding conclusion is in place, the residual risk of further claims and incalculable charges persists. Should the court confirm the settlement without material changes, the single largest drag in Bayer's corporate history loses its existential edge. Should the settlement fail or the process be delayed again, the uncertainty that has already absorbed substantial management capacity would simply extend.

The Operating Picture Behind the Legal Cloud

If the legal breakthrough comes, the underlying business argues for meaningful upside. Bayer generated group revenue of €10.87 billion in the second quarter of 2026, a currency- and portfolio-adjusted increase of 2.2%. Adjusted EBITDA rose 1.9% year over year to €2.14 billion, beating analyst consensus.

Crop Science did the heavy lifting, with its adjusted result climbing 30.2% to €902 million. Management is simultaneously sharpening the pharma portfolio. The sale of the cancer drug Stivarga to Grünenthal brings Bayer up to €375 million — a strategically coherent move given that Stivarga revenue fell 18% to €148 million in the first half of 2026 after patent expirations in China. The transaction is subject to customary conditions and is expected to close at the end of 2026 or the start of 2027.

Analysts have taken note. Deutsche Bank rated the stock "Buy" on September 10 with a price target of €60, while UBS had already reaffirmed its buy recommendation on September 1 with a €62 target. Both see considerable room to run if the agricultural business holds its strength and the legal pressure lifts.

Pipeline Progress on Two Fronts

Bayer is not standing still on research. Through its Leaps by Bayer investment arm, the company participated on September 17 in the Series A financing round of Robigo, aimed at developing biological crop protection solutions. A product against Sudden Death Syndrome in soybeans is slated for market launch in 2028. The agricultural division also reported advances in genome-edited sturdy soybeans and an herbicide tolerance matched to the active ingredient Icafolin.

In pharmaceuticals, Bayer launched a Phase II trial with the GIRK4 inhibitor BAY 3670549 for the treatment of atrial fibrillation. On the consumer side, the company introduced a new blister packaging made from polypropylene mono-material for its stomach remedy Talcid in Germany on Wednesday, improving recyclability, with a gradual rollout to further European markets planned.

What Could Still Go Wrong

Against the optimistic scenario stand substantial operational and legal risks. If the Missouri Circuit Court rejects the proposed class settlement or attaches conditions forcing Bayer into higher concessions, the balance sheet would take another hit and hopes for a near-term cleanup of legacy liabilities would suffer a serious setback.

The pharma division also faces structural headwinds beyond individual approval successes. The revenue decline at older products such as Stivarga illustrates the steady margin pressure created by expiring patent protection in key markets like China. New medicines must not only fill those gaps but overcompensate to put the group on a sustainable growth path. If the launch of new indications falls short of expectations, or if the agricultural business cools cyclically after a strong prior quarter, the recent share price recovery could quickly lose momentum.

The Setup for Investors

The situation is clearly contoured. As long as operating momentum in Crop Science persists and supports adjusted earnings, the stock rests on a solid foundation. But if the Missouri proceedings tip the other way and the court withholds final approval of the glyphosate settlement, the downside risk would come back in full force.

The next decisive trigger is the outstanding ruling from the Missouri Circuit Court. That decision will determine whether Bayer can complete the transition from a crisis-ridden restructuring case to a normally valued agricultural and pharmaceutical company. Until then, the risk-reward profile stays tightly tethered to legal developments in the United States.

In the meantime, the stock trades at €49.64, up 34% since the start of the year. The third quarter will come into focus on November 3, 2026, when management is scheduled to publish its quarterly statement.